![Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/46b58830-5146-408d-8954-2cf3bb2cf4f4/gr2.jpg)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
![Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer](http://article.cjcrcn.org/fileZGAZYJ/journal/article/zgazyj/2020/4/PIC/cjcr-32-04-xubinghe-2_mini.jpg)
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
![Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/98655565-88c3-426c-b446-8da9321bb7ff/gr1.jpg)
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
![Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00284-y/MediaObjects/41523_2021_284_Fig1_HTML.png)
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
![Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival – A retrospective multi-centre cohort study of ... Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival – A retrospective multi-centre cohort study of ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2019991837/2039853821/gr1.jpg)
Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival – A retrospective multi-centre cohort study of ...
![Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer](https://www.spandidos-publications.com/article_images/etm/22/1/etm-22-01-10179-g00.jpg)
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
![Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd52fc9d-a5d3-469a-b1aa-ad1d4704289a/gr6_lrg.jpg)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
![Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2608e663-265d-415f-805e-c1921e1e1d86/gr4.jpg)
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort
![IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer | HTML IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer | HTML](https://www.mdpi.com/ijerph/ijerph-17-02213/article_deploy/html/images/ijerph-17-02213-g001.png)
IJERPH | Free Full-Text | Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer | HTML
![Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12957-018-1424-4/MediaObjects/12957_2018_1424_Fig3_HTML.png)
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
![Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? - Annals of Oncology Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e388050b-71a0-4542-8864-44f7fb573807/gr1.jpg)
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? - Annals of Oncology
![Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fc2a5e846aba9993c4a5401d6df71a038c7d9a4a/2-Figure1-1.png)